AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00484939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Capecitabine was supplied as tablets.
Study NCT03936868 — intervention group
Intervention type: PROCEDURE
Intervention: Tendon transfer
Description: flexor carpi radialis transfer in most of patients and boye-transfer in very few
Study NCT00750867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous immunoglobulin (IVIg)
Description: The intravenous immunoglobulin (brand Privigen) will be infused intravenously, monthly, 6 times, for 6 months the dose will be 0.4 gram/kg for each infusion.
Study NCT03088345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin, Arginine
Description: Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
Study NCT03088345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
Study NCT03955731 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Magmaris resorbable magnesium scaffold
Description: Implantation of Magmaris resorbable magnesium scaffold
Study NCT03646955 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: No partial breast irradiation
Description: Omission of radiation therapy
Study NCT03644082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luminosity TrialChalk Board Challenge
Description: purpose is to problem solve quantitative reasoningequationsand to decide which card is greater or if the 2 cards are equal when the math problem is solved.
Study NCT03883113 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Sodium Chloride Placebo
Study NCT03883113 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H3N2 (A/Belgium/2417/2015)
Description: Challenge Agent
Study NCT00495274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: Formulation A represents the original formulation. SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing micronized drug substance. Formulation A will be administered in Part A.
Study NCT00495274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: Formulation B will represent SB-649868 10 mg film coated tablet containing micronized drug substance (3 tablets to reach 30 mg), but contains additional surfactant. Formulation B will be administered in Part A.
Study NCT00495274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C
Description: Formulation C will represent SB-649868 10 mg lipophilic capsule (3 capsules to reach 30 mg). Formulation C will be administered in Part A.
Study NCT00495274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D
Description: Formulation D will represent SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing nanomilled and spray dried powder. Formulation D will be administered in Part A.
Study NCT00495274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E
Description: Formulation E will represent SB-649868 10 mg capsule (3 capsules to reach 30 mg), containing nanomilled and spray dried powder. Formulation E will be administered in Part A.
Study NCT00495274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation F
Description: Formulation F will represent SB-649868 15 mg liquid filled capsule (2 capsules to reach 30 mg). Formulation F will be administered in Part A.
Study NCT03883113 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: H3N2 (A/Belgium/2417/2015)
Description: Challenge Agent
Study NCT02677844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT00495274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G
Description: Formulation G will be the selected formulation of SB-649868 30 mg to be assessed in Part B. The formulation will be administered after a standard FDA High-Fat breakfast
Study NCT03202641 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP ARDSnet
Description: PEEP settings based on the low PEEP/high FiO2 table
Study NCT03202641 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP LRM
Description: A lung recruitment maneuver (LRM) followed by PEEP guided by transpulmonary pressure.
Study NCT01032057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Study NCT01032057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Study NCT02677844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT02677844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT02677844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide
Description: Administered orally
Study NCT02677844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Administered orally
Study NCT01032057 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Study NCT01032057 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-dimensional conformal radiation therapy
Study NCT04187183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh Platelet Rich Plasma with leukocyte
Description: autologous Platelet Rich Plasma with leukocyte will be infiltrate in the knee joint
Study NCT04187183 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Platelet Rich Plasma without leukocyte
Description: autologous Platelet Rich Plasma without leukocyte will be infiltrate in the knee joint
Study NCT03111810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD4017 and prednisolone
Description: The drug AZD4017 will be given together with prednisolone 20mg daily for 7 days to compare its effects on metabolic tissues against the placebo arm where the participants will take placebo and prednisolone 20mg daily for 7 days.
Study NCT03111810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet and prednisolone
Description: Placebo Oral tablet will be given together with prednisolone 20mg daily for 7 days to compare the effects on metabolic tissues of AZD4017 and prednisolone 20mg daily against the placebo arm.
Study NCT00422955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Study NCT01854918 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection either every 2 weeks or once a month (patient preference) using a prefilled autoinjector pen
Study NCT02083887 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63 ME-TRAP / MVA ME-TRAP
Description: Intramuscular administration of ChAd63 ME-TRAP 5 x 10\^10 vp and MVA ME-TRAP 1 x 10\^8 pfu
Study NCT01854918 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab
Description: Administered by subcutaneous injection either every 2 weeks or once a month (patient preference) using a prefilled autoinjector pen
Study NCT01854918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
Study NCT01854918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
Study NCT00354627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC125
Description: 200 mg b.i.d. till commercially available.
Study NCT00788801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-614
Description: Baseline PET scan with radiotracer only, PET scan with radiotracer and ABT-614 Low Dose or ABT-614 High Dose
Study NCT02840760 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Stimulate the primary motor cortex for 2 weeks.
Study NCT02652286 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HARMONIC ACE+7
Description: Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy in humans
Study NCT04569890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol 200 MG/ML [Cimzia]
Description: CZP 200mg twice a week subcutaneous.
Study NCT04569890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: 400mg HCQ orally daily
Study NCT04569890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 10mg GC orally daily
Study NCT01305655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucarpidase
Description: Patients treated with Glucarpidase if the 24 hour levels of MTX is >250 µM, 36 hour levels >30 µM or 42 hours levels >10 µM together with a reduced kidney function will be compared with patients in just below the tricking values.
Study NCT03434314 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally-Invasive Segmental Artery Coil-Embolization
Description: During one single MISACE session 3-7 segmental arteries will be occluded. The procedure is conducted through a peripheral artery access in local anaesthesia. Microcoils or vascular plugs will be used for the occlusion itself.
Study NCT00053482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACAM2000 Smallpox Vaccine
Description: Group 1 dose: 1.0x10-8th PFU/ml, Group 2 dose: 2.0x10-7th PFU/ml, Group 3 dose: 1.0x10-7th PFU/ml, Group 4 dose: 5.0x10-6th PFUL/ml
Study NCT00053482 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®
Description: Group 5 dose: 1.0x10-8th PFU/ml
Study NCT01682694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucosamine and Chondroitin
Description: Glucosamine (1500 mg) and Chondroitin (1200 mg)
Study NCT01682694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03091569 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K Cream
Description: To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
Study NCT03829345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Patients will be administered olaparib orally twice daily (BD) at 300mg continuously for each 28 day cycle.
Study NCT00096018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00096018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Orally
Study NCT02949388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules (both containing Placebo enclosed) taken twice a day and approximately 12 hours apart
Study NCT02949388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400 mg (200 mg BID)
Description: Two capsules (both containing two 50mg tablets enclosed) taken twice a day and approximately 12 hours apart
Study NCT02949388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 300 mg (150 mg BID)
Description: Two capsules (one containing 50mg tablet and one containing two 50 mg tablets) taken twice a day and approximately 12 hours apart
Study NCT00921310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study NCT00921310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Study NCT03658070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XY0206
Description: Dosage form:Tablet;Single dose treatment:Take the drug once on day 1,each time 1 tablet. Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the criteria for stopping treatment or determine the duration and interval of treatment according to the accumulated condition after multiple dose.
Study NCT01221194 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy consisting of education, regular foot care and protective shoes and insoles. The standard therapy group will use the stockings they normally wear.
Study NCT01221194 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFC Stockings
Description: A pressure and friction reducing stocking. The novelty of the PFC Sock stems from its innovative double layer structure and technological fibre composition. These simultaneously and significantly reduce both pressure and friction in a format that is practical for everyday wear with therapeutic shoes in high-risk cases.
Study NCT03644082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luminosiuty Follow that Frog
Description: The purposeis to remember the path a red frog takes as it jump from lilypad to lily pad in a pond. This measures flexibility of thinking on a visual-motor sequencing task and working memory
Study NCT03644082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luminosity Train of Thought
Description: purpose is to guide specific colored trains into corresponding colored matching houses by attending to the different tracks. This measures divided attention.
Study NCT04577326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: A preconditioning regimen of one dose of intravenous (IV) cyclophosphamide 1.5 g/m\^2 will be administered 2-7 days before the infusion.
Study NCT00369486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40mg triamcinolone
Description: Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)
Study NCT00369486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg triamcinolone
Description: Anterior peribulbar injection of 20 mg triamcinolone
Study NCT00369486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40mg triamcinolone + laser
Description: Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser
Study NCT00369486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg triamcinolone + laser
Description: Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser
Study NCT02439970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brincidofovir
Study NCT01117935 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity modulated external beam radiation therapy
Description: Low risk - 69.6 Gy in 2.4 Gy fractions to prostate~Intermediate risk - delivered in 30 fractions with neoadjuvant and concurrent androgen deprivation therapy: 72 Gy in 2.4 Gy fractions to prostate + 60 Gy in 2 Gy fractions to seminal vesicles +/- 50.4 Gy in 1.68 Gy fractions to lymph nodes~High risk - 30 fractions with neoadjuvant, concurrent, and long term adjuvant androgen deprivation therapy: 72 Gy in 2.4 Gy fractions to prostate + 60 Gy in 2 Gy fractions to seminal vesicles +/- 50.4 Gy at 1.68 Gy fractions to lymph nodes
Study NCT05006144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sequenced trunk co-activation exercises
Description: * Sequenced trunk co-activation exercises were basically used for facilitation of functional activities through trunk musculature dynamic co-activation of in the lateral plane which is required for basic developmental milestones. In the frontal plane, encourage the child to actively shift his/her weight to maintain the weight-bearing side straight while keeping proper active co-activation of trunk musculature. Efficient trunk rotation is essential for acquiring of equilibrium reactions and balance. Enhancement of efficient active trunk rotation as the child could achieve active trunk musculature co-activation while maintaining the weight-bearing side straight (Arndt et al., 2008).~* Righting and protective reactions~* Functional stretching exercises.
Study NCT05006144 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sequenced trunk co-activation exercises
Description: * Sequenced trunk co-activation exercises were basically used for facilitation of functional activities through trunk musculature dynamic co-activation of in the lateral plane which is required for basic developmental milestones. In the frontal plane, encourage the child to actively shift his/her weight to maintain the weight-bearing side straight while keeping proper active co-activation of trunk musculature. Efficient trunk rotation is essential for acquiring of equilibrium reactions and balance. Enhancement of efficient active trunk rotation as the child could achieve active trunk musculature co-activation while maintaining the weight-bearing side straight (Arndt et al., 2008).~* Righting and protective reactions~* Functional stretching exercises.
Study NCT05006144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Orthotic Management
Description: A custom-made articulating ankle foot orthosis with a hinge at the level of the medial malleolus of the ankle is fabricated for each child from the same copolymer thermoplastic mold after casting with the subtalar joint in neutral position. The orthosis extended distally to the tip of the toes and proximally on the posterior surface of the leg to about 5 cm below the knee and secured to the foot by three straps across the forefoot, the front of the ankle, and to the anterior upper tibial portion. It is fabricated to permit free ankle dorsiflexion and lock the plantar flexion at 0 dorsiflexion. The splinting schedule started gradually for 2 h/day in the first month, 4 h/day in the second month to the entire wake-up time of the day in the third and fourth months to accommodate children to the orthosis.
Study NCT05006144 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Orthotic Management
Description: A custom-made articulating ankle foot orthosis with a hinge at the level of the medial malleolus of the ankle is fabricated for each child from the same copolymer thermoplastic mold after casting with the subtalar joint in neutral position. The orthosis extended distally to the tip of the toes and proximally on the posterior surface of the leg to about 5 cm below the knee and secured to the foot by three straps across the forefoot, the front of the ankle, and to the anterior upper tibial portion. It is fabricated to permit free ankle dorsiflexion and lock the plantar flexion at 0 dorsiflexion. The splinting schedule started gradually for 2 h/day in the first month, 4 h/day in the second month to the entire wake-up time of the day in the third and fourth months to accommodate children to the orthosis.
Study NCT05006144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selective dorsal rhizotomy
Description: All SDRs were performed by a single neurosurgeon through an osteoplastic laminotomy from L2 to L5 that left the facet joints intact. After opening the dura, the posterior nerve roots of L2 to S1 were identified and divided into 3 to 6 rootlets. At L2, from 30% to 50% of the posterior nerve rootlets were sectioned without selective stimulation. Selective electric stimulation of each nerve rootlet was performed from L3 to S1. The percentage of rootlets sectioned at each level (table 3) was determined by the surgical team based on the electromyographic results obtained intrasurgically and knowledge of the presurgical assessment results. The laminae were replaced on the completion of the rootlet stimulation and secured with sutures in the yellow ligament and the supraspinous ligament.
Study NCT04577326 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T cells
Description: A single dose of M28z1XXPD1DNR CAR T cells will be instilled into the pleural cavity via a pleural catheter or through an interventional radiology-guided needle. Cohorts of 3 patients will be treated at each dose level, up to a maximum of 3 x 10\^7 T cells/kg or until the MTD has been reached.
Study NCT00916110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: 1.5 mg solution, single subcutaneous injection
Study NCT02439970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir